Gilead climbs on 1Q15 earnings

Gilead Sciences Inc. (NASDAQ:GILD) gained $4.52 to $105.03 on Friday, adding $6.7 billion in market cap to $156 billion as investors reacted to the company's 1Q15 earnings, released after market close on Thursday.

The biotech beat the Street's estimate and raised its 2015 full year net product sales guidance to $28-$29 billion from $26-$27 billion. The company also revealed additional details about the level of access its HCV drugs Harvoni ledipsavir/ sofosbuvir and Sovaldi sofosbuvir have on formularies (see BioCentury Extra, April 30). ...